Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 835-846

  Nielsen, Loretta L ^a   Lipari, Philip ^a   Dell, Janet ^a   Gurnani, Maya ^a   Hajian, Gerald ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL CYCLE; DRUG EFFICACY; DRUG POTENTIATION; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MICROTUBULE; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, P53; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICROTUBULES; NEOPLASMS; OVARIAN NEOPLASMS; PACLITAXEL; PROSTATIC NEOPLASMS; TRANSDUCTION, GENETIC; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0031944077     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Ozbun, M. A., and Butel, J. S. Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv. Cancer Res., 66: 71-141, 1995.
2. Selter, H., and Montenarh, M. The emerging picture of p53. Int. J. Biochem., 26: 145-154, 1994.
3. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 267: 1456-1462, 1995.
4. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
5. Nielsen, L. L., and Maneval, D. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther., 5: 52-63, 1998.
6. Horwitz, S. B. Mechanism of action of Taxol. Trends Pharmacol. Sci., 13: 134-136, 1992.
7. Rowinsky, E. K., Cazenave, L. A., and Donehower, R. C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. (Bethesda), 82: 1247-1259, 1990.
8. Donaldson, K. L., Goolsby, G. L., and Wahl, A. F. Cytotoxicity of the anticancer agents cisplatin and Taxol during cell proliferation and the cell cycle. Int. J. Cancer, 57: 847-855, 1994.
9. 2-M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
10. Berenbaum, M. C. What is synergy? Pharmacol. Rev., 41: 93-141, 1989.
11. Wills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M-T., Huang, W-M, Johnson, D. E., Anderson, S. C., Wen, S. F., Bookstein, R., Shepard, H. M., and Gregory, R. J. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther., 5: 1079-1088, 1994.
12. Harris, M. P., Sutjipto, S., Wills, K. N., Hancock, W., Cornell, D., Johnson, D. E., Gregory, R. J., Shepard, H. M., and Maneval, D. C. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther., 3: 121-130, 1996.
13. Nielsen, L. L., Dell, J., Maxwell, E., Armstrong, L, Maneval, D., and Catino, J. J. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther., 4: 129-138, 1997.
14. Bartek, J., Iggo, R., Gannon, J., and Lane, D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5: 893-899, 1990.
15. Isaacs, W. B., Carter, R. S., and Ewing, C. M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res., 51: 4716-4720, 1991.
16. Yaginuma, Y., and Westphal, H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res., 52: 4196-4199, 1992.
17. Jung, M., Notario, V., and Dritschilo, A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res., 52: 6390-6393, 1992.
18. Caamano, J., Zhang, S. Y., Rosvold, E. A., Bauer, B., and Klein-Szanto, A. J. P. p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am. J. Pathol., 142: 1131-1139, 1993.
19. Min, B., Baek, J., Shin, K., Gujuluva, C. N., Cherrick, H. M., and Park, N. Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines. Eur. J. Cancer, 30B: 338-345, 1994.
20. Huyghe, B. G., Liu, X., Sutjipto, S., Sugarman, B. J., Horn, M. T., Shepard, H. M., Scandella, C. J., and Shabram, P. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum. Gene Ther., 6: 1403-1416, 1995.
21. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 64: 55-63, 1983.
22. Greco, W. R., Bravo, G., and Parsons, J. C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev., 47: 331-385, 1995.
23. Harder, R. L., and Desmarais, R. N. Interpolation using surface splines. J. Aircraft, 9: 189-191, 1972.
24. SAS Institute Inc. SAS/GRAPH Software: Reference, Version 6, Ed. 1, Vol. 2. Cary, NC: SAS Institute Inc., 1990.
25. Snyder, W. V. Contour plotting [J6]. ACM Trans. Math. Software, 4: 290-294, 1978.
26. Berenbaum, M. C. Criteria for analyzing interactions between biological active agents. Adv. Cancer Res., 35: 269-333, 1981.
27. Carter, W. H., Gennings, C., Staniswalis, J. G., Campbell, E. D., and White, K. L. A statistical approach to the construction and analysis of isobolograms. J. Am. Coll. Toxicol., 7: 963-973, 1988.
28. SAS Institute Inc. SAS/STAT Software. Changes and Enhancements through Release 6.12. Cary, NC: SAS Institute Inc., 1997.
29. O'Connell, and Wolfinger, R. D. Spatial regression models, response surfaces, and process optimization. J. Comput. Graph. Stat., 6: 224-241, 1997.
30. Debernardis, D., Sire, E. G., De Feudis, P., Vikhanskaya, F., Valenti, M., Russo, P., Parodi, S., D'Incalci, M., and Broggini, M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res., 57: 870-874, 1997.
31. Christen, R. D., Jekunen, A. P., Jones, J. A., Thiebaut, F., Shalinsky, D. R., and Howell, S. B. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J. Clin. Invest., 92: 431-440, 1993.
32. L and bak expression. Clin. Cancer Res., 3: 2039-2046, 1997.
33. Jordan, M. A., Toso, R. J., Thrower, D., and Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc. Natl. Acad. Sci. USA, 90: 9552-9556, 1993.
34. Derry, W. B., Wilson, L., and Jordan, M. A. Substoichiometric binding of Taxol suppresses microtubule dynamics. Biochemistry, 34: 2203-2211, 1995.
35. Zheng, M., Cerniglia, G. J., Eck, S. L., and Stevens, C. W. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum. Gene Ther., 8: 1025-1032, 1997.
36. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W-W., Owen-Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
37. Nguyen, D. M., Spitz, F. R., Yen, N., Cristiano, R. J., and Roth, J. A. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J. Thorac. Cardiovasc. Surg., 112: 1372-1377, 1996.
38. Gjerset, R. A., Turla, S. T., Sobol, R. E., Scalise, J. J., Mercola, D., Collins, H., and Hopkins, P. J. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol. Carcinog., 14: 275-285, 1995.
39. Yang, B., Eshleman, J. R., Berger, N. A., and Markowitz, S. D. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin. Cancer Res., 2: 1649-1657, 1996.
40. Blagosklonny, M., and El-Deiry, W. S. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int. J. Cancer, 67: 386-392, 1996.
41. Spitz, F. R., Nguyen, D., Skibber, J. M., Meyn, R. E., Cristiano, R. J., and Roth, J. A. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin. Cancer Res., 2: 1665-1671, 1996.
42. Gallardo, D., Drazan, K. E., and McBride, W. H. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res., 56: 4891-4893, 1996.